Keep ROP eligibility, treatment indication and post-treatment follow-up separate. In adult glaucoma screening, confirm suspicious findings and distinguish strong recommendations from the lower evidence supporting interval choices.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Recognise immaturity and classify retinal activity
Retinopathy of prematurity (ROP), also called Retinopathia praematurorum (RPM), follows disturbed retinal vascular development after premature birth. Severe disease can lead to tractional retinal detachment and permanent visual loss; timely screening and treatment reduce that risk but cannot guarantee normal vision. 2
Normal retinal vessels develop during fetal life and continue towards the periphery. The historical German 2020 guideline describes development between 16 and 40 gestational weeks and approximately 70% of vessels formed by 27 weeks; ICROP3 describes an onset around 13 weeks. These approximate developmental descriptions are not interchangeable screening thresholds, and the underlying developmental reference still needs reconciliation. 2 4
After birth, pulmonary gas exchange increases oxygen availability relative to the intrauterine environment. In the first phase, relative hyperoxia suppresses hypoxia-regulated growth signals, including vascular endothelial growth factor (VEGF), and interrupts normal vascular growth. 2
As the incompletely vascularised retina matures, its oxygen demand rises. The second phase, described around 32–34 weeks postmenstrual age (PMA), involves relative hypoxia, hypoxia-inducible factor 1 (HIF-1) and increased VEGF signalling. Excess disorganised vessels may grow beyond the retinal plane; accompanying fibrous tissue can contract and detach the retina. 2
Liver-derived insulin-like growth factor 1 (IGF-1) modulates vascular development. Poor nutrition or postnatal growth, necrotising enterocolitis (NEC) and sepsis can accompany low IGF-1; that association does not prove that replacement prevents ROP. 2 10
A phase 2 randomised IGF-1/IGFBP-3 replacement trial enrolled 121 infants born at 23+0–27+6 weeks:61 received treatment and 60 standard care. The regimen did not improve the primary ROP severity outcome; only 24 of 61 treated infants achieved target exposure. Secondary bronchopulmonary dysplasia findings do not establish a ROP-prevention indication or show that every future replacement strategy must fail. 10
Immaturity at birth is the main risk factor. Oxygen exposure matters, but oxygen is also life-saving neonatal treatment: never reduce prescribed supplementation independently to try to prevent ROP. 2 9
NeOProM combined individual data from five randomised trials in 4965 infants born before 28 weeks, comparing target oxygen saturation 85–89% with 91–95%. Death or major disability at 18–24 months occurred in 53.5% versus 51.6%; the trial-based risk difference was 1.7 percentage points (95% CI−1.3 to 4.6), with RR1.04 (0.98–1.09), P=.21. This non-significant composite result does not establish equal safety. 9
Lower targets reduced treatment-requiring ROP:220/2020 (10.9%) versus 308/2065 (14.9%), risk difference−4.0 percentage points (95% CI−6.1 to−2.0). They also increased death, 484/2433 (19.9%) versus 418/2440 (17.1%), and severe NEC, 227/2464 (9.2%) versus 170/2465 (6.9%). These are different endpoint denominators; competing mortality and multiple secondary outcomes limit an isolated eye-focused interpretation. 9
Other reported associations include intrauterine growth restriction, poor postnatal weight gain, formula rather than human milk, thrombocytopenia during infection, systemic fungal infection, parenteral nutrition without polyunsaturated fatty acids, haemodynamic stress in the first month and hypoxaemia from the second month. Keep each factor in its neonatal context: confounding by illness severity and care makes association different from a proven preventive intervention. 2
Genetic susceptibility is also being studied, including brain-derived neurotrophic factor (BDNF). Candidate-gene associations and NGF/TH/BDNF interactions are exploratory; they do not establish causation or a validated test for deciding which infant can safely skip screening. Different studies do not reproduce every gene signal. 2 13 14 15
The clinical course includes a latent period, an acute phase that may progress quickly, and regression in many mild cases. The 2020 guideline attributes adverse outcomes despite cryotherapy to about 50% of zone II stage 3+ eyes and over 90% of zone I stage 3+ eyes in historical CRYO-ROP reports. The underlying zone-specific tables and follow-up times remain unchecked; these are not current individual prognosis figures, and adverse structure is not synonymous with blindness. 2 18
The International Classification of Retinopathy of Prematurity, third edition (ICROP3), standardises the description. It is expert consensus, not a stand-alone treatment trial: combine the classification with the infant’s course and the applicable clinical guideline. 4
Zone I is centred on the optic disc, with a radius twice the disc-centre–fovea distance. With a 28 D lens, placing the nasal disc edge at the field edge helps approximate the temporal zone I boundary; this is an examination aid, not a replacement for careful localisation. 4
Zone II extends from zone I to the nasal ora serrata. ICROP3 defines posterior zone II as the region extending two disc diameters beyond the zone I boundary; the original shortcut using a radius of three disc–fovea distances is not equivalent. 4
Zone III is the remaining temporal crescent. Confirm that the nasal retina is vascularised to the ora serrata and that disease does not remain in the nasal two clock hours before assigning zone III; an apparently peripheral temporal lesion alone is insufficient. 4
Stage 1 is a demarcation line between vascularised and avascular retina; stage 2 is an elevated ridge. Stage 3 has extraretinal fibrovascular proliferation, which can be flat and difficult to recognise without an obvious ridge, particularly in aggressive disease. 4
Stage 4 is partial retinal detachment:4A leaves the fovea attached, whereas 4B involves the fovea. Stage 5 is total detachment, often funnel-shaped; ICROP3 further describes 5A with the disc visible, 5B without a visible disc, and 5C with additional anterior-segment changes. These findings require specialist retinal assessment. 4
Plus disease describes sufficiently severe vascular dilation and tortuosity; pre-plus lies between normal and plus on a continuum. The historical criterion uses at least two quadrants, while ICROP3 emphasises vascular assessment within zone I rather than a quadrant count alone. Observer variation remains relevant, so document the finding and uncertainty instead of treating the label as an infallible binary test. 2 4
Aggressive ROP (A-ROP), historically aggressive posterior ROP (AP-ROP or rush-type disease), may progress rapidly without the usual stage sequence. Marked plus changes, shunts, haemorrhage and a flat neovascular network can be disproportionate to the visible ridge. The newer name recognises that this pattern can occur beyond the posterior retina and in larger preterm infants. 2 4
Also record iris hyperaemia, rubeosis iridis, vitreous haze, retinal or vitreous haemorrhage and poor pharmacological dilation. A persistent tunica vasculosa lentis (TVL), the fetal vascular covering of the lens, is a developmental finding; unusually dilated, tortuous vessels can accompany active severe ROP. 2 4
The immature eye may have corneal or vitreous haze and persistent fetal vessels, including tunica vasculosa lentis. The export’s absent pupillary light response before 30 weeks and regular response from 35 weeks are approximate developmental observations, not ROP exclusion criteria; interpret them with maturity and examination conditions. 26
| Stage | Finding |
|---|---|
| 1 | Demarcation line |
| 2 | Elevated ridge |
| 3 | Extraretinal fibrovascular proliferation, sometimes flat without obvious ridge |
| 4A | Partial detachment without foveal involvement |
| 4B | Partial detachment involving the fovea |
| 5 | Total retinal detachment; ICROP3 further subdivides it |
02Plan and perform screening
Screening criteria differ between countries and editions. The schedules below describe the directly inspected German 2020 guideline; the German July 2026 screening edition is located but its full clinical text has not yet been checked. These historical schedules must not be used as a verified 2026 protocol without that reconciliation. 1 2 3
The German 2020 guideline includes infants born before 31+0 gestational weeks, regardless of supplemental oxygen. If gestational age is uncertain, it uses birthweight below 1500 g. Its reduction from the previous 32+0 week boundary drew on a 2011–2018 registry series of 281 treated infants in which none had been born at 31+0 to<32+0 weeks; absence in that selected registry does not prove zero risk. 2
More mature preterm infants born before 37+0 weeks are considered when the neonatologist judges ROP risk, for example after more than 5 days of supplemental oxygen, extracorporeal membrane oxygenation (ECMO), severe NEC, bronchopulmonary dysplasia, sepsis or transfusion-requiring anaemia. The discretion and associated illnesses are part of the rule. 2
For comparison, the UK2024 summary includes GA below 31 weeks OR birthweight below 1501 g and adds consideration of infants born at 31+0–31+6 weeks. Its age schedule also differs. Do not silently import either the UK OR rule or its examination timing into the German pathway. 3
The historical German first examination is in the sixth postnatal week, days 36–42, but not beforePMA 31+0 weeks. PMA is gestational age at birth plus age since birth. The original wrapper’s “32 postconceptional weeks or weight below 1500 g, whichever comes first” confuses eligibility and timing and is not an acceptable substitute. 2
For untreated ROP, the German 2020 default interval is two weeks. Shorten to one week when the vascular front is in zone I or posterior zone II, irrespective of ROP stage; also use one-week intervals for anterior zone II stage 2 or 3 or any ROP with plus disease. Rapid progression or extreme immaturity can require even earlier examination. 2
The same historical schedule permits three-week intervals when the vascular front is in zone III without ROP. It permits adding one week after regression over several examinations or after the expected due date; these are conditional allowances, not automatic extensions for every infant. 2
Without treatment, historical German screening can end after complete circumferential peripheral vascularisation, or after clear peripheral regression only once the expected due date has passed. Discharge does not end the indication: severe disease can emerge after the baby has gone home. Treated infants need a separate follow-up plan. 2
ROP screening requires an examiner experienced with premature infants, indirect ophthalmoscopy and ROP classification. Wide-field imaging can document findings and support telemedicine, but it must show the relevant peripheral retina; a limited image is not proof of a normal periphery. 2 3
Arrange dilation, neonatal support and analgesia under the local protocol, with attention to systemic effects. The German 2020 examples include tropicamide 0.5% and phenylephrine 2%; the UK2024 summary instead describes phenylephrine 2.5% with cyclopentolate 0.5%, with tropicamide as an alternative. These are jurisdiction-specific examples, not a universal prescription for a preterm infant. 2 3
A second person helps support the infant and head, with neonatal staff available. Topical anaesthetic before a speculum or lid hook and comfort measures such as non-nutritive sucking or glucose/sucrose reduce distress. Monitor the infant and keep the examination as brief as an adequate assessment permits. 2 3
Binocular indirect ophthalmoscopy permits stereoscopic assessment and gentle rotation to inspect the far peripheral vascular front. A speculum and scleral indentor may assist an experienced examiner; imaging equipment and reusable instruments require appropriate handling, disinfection and manufacturer guidance. 2 3
Use a consistent sequence: inspect the anterior segment and TVL first, then the central retina and finally the peripheral retina through 360 degrees. Record vascular extent, zone, stage, clock-hour extent, plus/pre-plus, haemorrhage and any traction or detachment. 2
Do not mistake reduced vessel calibre for true regression when arterial oxygen has changed or a camera has pressed too firmly on the eye. Distinguish retinal vessels from choroidal vessels when estimating vascularisation; posterior or aggressive disease can be underestimated if only a ridge is sought. 2
End every examination with a written decision: the next appointment, a treatment/referral plan with urgency, or documented satisfaction of stopping criteria. If the view is inadequate or the infant cannot tolerate a complete examination, arrange an explicit senior plan rather than recording the retina as normal. 2 3
03Choose treatment using the correct evidence
Treatment depends on location, activity and progression, not just a clock-hour count. Historical threshold disease describes zone II stage 3 with plus over at least 5 contiguous or 8 noncontiguous clock hours. Waiting for that extent can delay treatment in higher-risk disease. 2 5 11
ETROP type 1 includes zone I ROP of any stage with plus, zone I stage 3 without plus, and zone II stage 2 or 3 with plus. Type 2 includes zone I stage 1 or 2 without plus and zone II stage 3 without plus and requires observation for progression. Distinguish this trial-derived framework from the original German 2020 discussion of zoneII3+ treatment from one clock hour and from current national recommendations still being reconciled. 5
A report of zone III disease does not justify ignoring plus, stage 3 or aggressive activity: reassess localisation and refer to an experienced treating specialist. The historical guideline’s “usually no treatment in zone III even with plus” is not a blanket reassurance rule. 2 3 4
Once treatment is indicated, agree urgency with ophthalmology, neonatology and anaesthesia and explain the plan to the parents. Rapid aggressive disease may need treatment within 24 hours; ordinary scheduling must not delay an eye that is deteriorating quickly. 2 4 11
Laser photocoagulation treats the avascular peripheral retina and is an established option for treatment-requiring ROP. Cryotherapy remains relevant historically and in selected exceptional circumstances; comparison studies favoured laser outcomes. Laser leaves ablated peripheral retina, whereas anti-VEGF may permit further vascularisation but can leave persistent avascular areas and delayed reactivation. Intravitreal anti-VEGF treatment inhibits the VEGF signal driving pathological vessel activity; laser instead reduces the stimulus from treated avascular retina. 2 5 11
ETROP randomised 401 infants, including 317 bilateral paired-eye cases and 84 asymmetric cases, to early treatment or conventional management. At 9 months corrected age, the proportion with unfavourable grating visual acuity decreased from 19.5% to 14.5%(P=.01), and the proportion with adverse structure from 15.6% to 9.1%(P<.001). The eye-pair design and infant grating outcome are not interchangeable with long-term everyday visual function. 5
BEAT-ROP randomised 150 infants with bilateral stage 3+ ROP in zone I or posterior zone II to bevacizumab 0.625 mg/0.025 ml or laser. Among 143 survivors assessed toPMA 54 weeks, recurrence affected 6/140 eyes(4%;4 infants) versus 32/146 eyes(22%;19 infants), P=.002. The zone I signal was significant(P=.003), whereas posterior zone II was not(P=.27); seven deaths were excluded from the primary surviving cohort, and the trial was too small to establish safety. 6
RAINBOW was an open-label superiority trial of 225 randomised infants with birthweight below 1500 g receiving ranibizumab 0.2 mg, 0.1 mg or laser. At 24 weeks, success was 56/70 (80%), 57/76 (75%) and 45/68 (66%) among the primary assessed populations. For 0.2 mg versus laser, OR2.19 (95% CI0.99–4.82), P=.051: the primary superiority test was not met, despite the numerically higher success rate. 7
RAINBOW’s interpretation also depends on withdrawal and incomplete follow-up, hierarchical testing and its Novartis sponsorship. Seven infants withdrew before treatment;17 had incomplete 24 week follow-up, including four deaths per group. The primary outcome is not proof of a universal structural or visual advantage of the drug class. 7
FIREFLEYE provides randomised aflibercept evidence, correcting the old claim that it had only case reports or retrospective series. Of 118 randomised infants, 113 were treated:75 with aflibercept 0.4 mg and 38 with laser. At 24 weeks, success was 85.5% versus 82.1%; the difference was 3.4 percentage points, but the one-sided 95% Bayesian credible interval extended from−8.0 to∞against a −5 point margin. Non-inferiority was not met; this does not demonstrate inferiority, equivalence or superiority. 8
FIREFLEYE’s per-eye rescue rates, 4.8% versus 11.1%, use a different unit from infant-level primary success.104 infants completed the trial. Three deaths in the aflibercept arm were judged unrelated by investigators; small safety datasets cannot exclude uncommon systemic harm. Cross-trial percentages cannot establish the best anti-VEGF agent. 8
Drug approval and dose depend on the agent, formulation, indication and jurisdiction. Ranibizumab and aflibercept have EU ROP indications, so a blanket “anti-VEGF is off-label” statement is outdated; bevacizumab use remains distinct. The German S1v 1.2 records ranibizumab 0.2 mg/0.02 ml and corrected aflibercept 0.4 mg/0.01 ml. These small volumes require appropriate delivery; the current local product information and device instructions must be checked before treatment. The original also names conbercept; its current comparative evidence and local authorisation remain unverified here. Bevacizumab (Avastin), ranibizumab (Lucentis) and aflibercept (Eylea) must remain distinct agents, not interchangeable names or formulations. 11 12
Lower-dose research does not establish one optimal dose for every infant. Systemic transfer and VEGF suppression, particularly after bevacizumab, have been reported, with historical observations up to three months; ranibizumab appears to have less or shorter systemic VEGF suppression in some studies. These pharmacokinetic findings are not direct proof of neurodevelopmental injury or proof that an alternative is systemically harmless. Hypotension after injection has also been reported. 2 11
At five years in the RAINBOW extension, 156 of 180 enrolled children were assessed;180 had entered from 201 core completers, rather than from all 225 randomised infants.124 completed letter-acuity testing. Better-eye means were 66.8, 64.6 and 62.1 letters; the 0.2 mg–laser difference of 4.7 letters had 95% CI−1.1 to 10.5, so a visual-acuity advantage was not established. 11 16
High myopia worse than−5 D occurred in 4/52 (8%) after 0.2 mg, 8/55 (15%) after 0.1 mg and 11/45 (24%) after laser. This supports discussion of refractive outcomes, with attrition, survivor selection, different testing methods and sponsorship kept in view. No detected nonocular developmental difference is not proof that rare or long-term harm is absent. 16
Stages 4 and 5 may require vitrectomy and/or scleral buckling in a specialist retinal centre. Functional outcomes are generally poorer than after successful earlier treatment. Existing traction also matters when considering anti-VEGF because contraction can worsen the retinal configuration; surgery, drug treatment and laser need an individual plan. 2 11
04Secure follow-up and define age correctly
After laser, the historical German schedule starts with examinations at least weekly until activity has reliably regressed and all relevant avascular areas have been adequately treated. Intervals can then increase as the retina stabilises without active proliferation, traction or plus. Do not wait for complete vascularisation of retina that has been intentionally ablated. 2 11
The original wrapper instead suggested 1–2 weekly checks and a universal stop at 50–55“postconceptional” weeks. That conflicts with the fuller lecture and is not a general follow-up rule. Decide frequency and stopping from the treatment, retinal findings and applicable current protocol. 2 11
After intravitreal anti-VEGF, arrange early postoperative checks for infection and injection-related complications. The inspected S1 text calls for at least one review within the first 4 days, assessing such concerns as perfusion, pressure, lens injury and retinal complications as appropriate; later reviews must still track disease activity. 2 11
When drug activity wanes, ROP can reactivate well after the expected due date or hospital discharge. Historical reports include recurrence atPMA 69 weeks or 35 weeks after the last injection. Neither number is a guaranteed safe stopping threshold, and early regression does not justify losing the infant to follow-up. 2 11
Historical German stopping options after anti-VEGF include complete vascularisation; adequate laser of residual avascular retina without treatment-requiring activity; or a stable inactive vascular pattern over several months despite residual avascular retina. The last option requires specialist judgment, explicit documentation and reconciliation with current guidance; persistent avascular retina is not automatically normal. 2 11
Use a written ROP-pass or equivalent handover containing treatment and examination dates, the latest findings, the receiving clinicians and the next appointment. Arrange that appointment before discharge and explain why missing it can allow silent progression. 2 3 11
Long-term care addresses refractive error, myopia, strabismus and visual development even after successful acute treatment. Later retinal or vascular changes can occur years afterwards, but a claim about late new vessels needs its specific context and source rather than assuming every treated child has ongoing acute ROP. Acute screening completion and long-term ophthalmic care are separate decisions. 2 3 16
Gestational age (GA) describes maturity from the first day of the last menstrual period and is recorded in completed weeks and days:28+5 means 28 weeks plus 5 days. Postnatal age (PNA) is elapsed age since birth; postmenstrual age (PMA) is GA at birth plus PNA. The commonly substituted term “postconceptional” is not equivalent. 2 4
A-ROP retains the original AP-ROP concept while broadening its location; it denotes a rapidly progressive vascular pattern, sometimes with shunts and flat proliferation. Plus and pre-plus describe a vascular severity continuum, not merely the presence or absence of a ridge. 2 4
Threshold disease is the historical clock-hour definition, not a synonym for all treatment-requiring ROP. TVL is the fetal vascular covering of the lens. “Immature retina” means incomplete vascularisation without ROP; record the zone, and prefer the more precise ICROP3 description of incomplete vascularisation. 2 4 5
Additional findings to document include iris hyperaemia or rubeosis, vitreous haze, retinal/vitreous haemorrhage and limited dilation. They complement zone, stage, extent and vascular activity rather than replacing those descriptors. 2 4
05Assess adult glaucoma risk
Open-angle glaucoma involves progressive neuroretinal rim and retinal nerve fibre layer (RNFL) loss with corresponding visual-field damage. Early symptoms may be absent; risk assessment, detection, treatment and follow-up all contribute to care, so risk quantification is not the only means of preventing disability. 21 22
The DOG/BVA S2e update dated 3 March 2024 addresses adult risk and early detection, largely using populations of European ancestry; it does not set management for known glaucoma or diagnosed ocular hypertension. A strong A recommendation can coexist with evidence level 3 and expert consensus; Oxford 2011 levels and A/B/0 grades answer different questions. 22
The original reports advanced damage in about 1/3 and driving ineligibility in 10–20% at diagnosis. Those proportions require their populations, binocular-field criteria and jurisdiction; no individual driving decision follows from a diagnosis or these percentages alone. 21
At age 40–80, the original summarises 5-year incidence as 0.5–1.5%, Rotterdam 0.6% over 5 years and northern Sweden 0.9% per year over 21 years. Different cohorts and observation periods cannot be combined into a personal annual risk. 21 22
Prevalence increases with age; the original 2.0–2.5-fold increase per decade from age 40 and 1.3-fold male prevalence are group associations, not individual forecasts. First-degree family history is associated with about 2.0–3.0-fold risk, but reporting and ascertainment affect the estimate. 21 22
The original approximately 3-fold estimate for darker-skinned populations and earlier onset, and rising risk with age in Latin American populations, need population-specific context. Skin colour is an imprecise proxy for ancestry and social factors; do not infer an individual genetic risk or a universal coefficient from appearance. 21 22
The lecture gives European glaucoma prevalence at age 40–80 as 2.93%, including 2.51% open-angle glaucoma. Its age examples are 0.4% at 40;2.7% at 70 and 10.0% at 90; definitions and population matter, and extrapolating beyond the sampled ages is unsafe. 21 22
The original age-specific incidence rates are 1.3,2.5,4.2 and 7.1 per 1000 person-years at 40–49;50–59;60–69 and≥70 years. Its prevalence examples at 40;50;60;70;80 and 90 years are 0.4%,0.7%,1.4%,2.7%,5.3% and 10.0%. Rates, prevalence and personal future probability remain distinct. 22
06Interpret pressure, structure and medication
Intraocular pressure (IOP) is the established treatment target, but high IOP is not synonymous with glaucoma. OHTS randomised 1636 selected patients aged 40–80 without glaucomatous damage, with IOP 24–32 mmHg in one eye and 21–32 in the other. At 60 months estimated glaucoma incidence was 9.5% with observation versus 4.4% with medication: HR 0.40, 95% CI 0.27–0.59. 21 23
The original 9% for every eye ≥24 mmHg overgeneralises and rounds the trial. Its 9.5% is a Kaplan–Meier estimate, not the raw 89/819=10.9% proportion; open treatment, masked endpoint assessment, attrition and allocation deviations matter. The CCT-adjustment study concerns risk prediction, not tonometer accuracy; central corneal thickness (CCT) does not justify a universal corrected-IOP formula. 23 24
Cup-to-disc ratio (CDR) ≥0.6 at an average-sized disc or inter-eye asymmetry ≥0.2 increases suspicion; the latter LR 3.9–4.1 is a diagnostic likelihood ratio, not a future-risk multiplier. Disc haemorrhage original 7.5-fold refers to prevalent association, not guaranteed progression; disc size, rim, fields and imaging must be assessed. 21 22
Myopia of magnitude ≥4 dioptres, conventionally ≤−4 D, and pseudoexfoliation (PEX) deserve closer assessment. Original estimates 2.3-fold for myopia and 4–6-fold for PEX depend on population and design and should not be multiplied together as an individual risk score. 21 22
The original myopia estimates are 2–3-fold from magnitude 4D and 1.5-fold per additional millimetre of axial length. These observational associations are neither additive nor a validated individual calculator. In pseudophakia, look for PEX beyond the absent natural anterior lens capsule: pupillary border, angle, deposits and prior records can help; “lens-periphery deposits only” is inadequate. 21 22
A vertical CDR≥0.6 in an average-sized disc has reported positive LR7.0–7.5; inter-eye difference≥0.3 has LR7.3. Neither a diagnostic LR nor a prevalent disc-haemorrhage association should be relabelled as future conversion probability. 21 22
Topical ocular, intravitreal and systemic steroids can raise IOP. The original up to 79% after 2.1 mg fluocinolone is a historical preparation- and definition-specific estimate; it does not describe every current implant, steroid response or glaucoma incidence. 21 22
The guideline discusses inhaled high doses, historically >4 puffs for at least 3 months, especially with family history. Different inhalers deliver different doses; this is not a safe no-risk threshold. Its intranasal review found no clinically important group increase, which does not prove zero individual risk or justify changing systemic treatment without coordination. 21 22
The original diabetes/hypertension associations of 1.16–1.4 require study-specific interpretation. Shared age and vascular factors, ascertainment and more frequent examinations can confound associations; neither condition proves a glaucomatous optic neuropathy. 21 22
The guideline discusses diabetes association 1.48 and hypertension 1.16, with inconsistent causality. Exploratory renal associations include uric-acid/creatinine ratio OR1.04 (95% CI1.01–1.07) and macroalbuminuria OR8.00 (2.97–21.5); a wide interval and observational design preclude treating these as established screening factors. 21 22
The historical intravitreal comparisons include pressure rise in 15% after dexamethasone 0.7 mg and 79% after fluocinolone 2.1 mg. These are different preparations, populations and definitions, not a head-to-head comparison or a current-dose recommendation. 21 22
The original separates about 2-fold incident association from 3-fold prevalent association for first-degree family history. These are different study questions and ascertainment methods, not interchangeable personal risk multipliers; relatives and reporting bias matter. 26
07Explain screening and set the next interval
DOG/BVA recommends offering screening from age 40, including binocular disc examination and IOP; recommendations 4-3 and 4-4 are strong but have evidence level 3. The historical 64% sensitivity/96% specificity estimate has selection/definition limits, including classifying IOP <18 mmHg as healthy; it is not universal test performance. 22
The Swedish screening follow-up reported blindness RR 0.52 over about 20 years after one screen at age 50–80. This observational follow-up is not the randomised EMGT treatment effect or proof that screening halves every individual risk. Discuss false positives, missed disease and the need to confirm a result. 21 22
A single IOP value cannot exclude OHT or glaucoma. The cited 5.3–6.9 mmHg between-day variation concerns a selected measurement series, not a universal instrument error. Suspicion leads to repeated IOP, perimetry, structural assessment, gonioscopy and pachymetry as appropriate before a treatment decision. 21 22
The lecture’s tonometry sensitivity about 30% at a cutoff>21mmHg and combined specificity 96% concern different test definitions and selected studies. They do not give one universal sensitivity/specificity pair; morphology, field, imaging and clinical context are needed. 21 22
The interval table preserves the four original risk groups. These are 2024 German expert-consensus screening intervals after excluding glaucoma, not a schedule for symptomatic patients or established disease. Relevant additional factors include first-degree family history, myopia magnitude ≥4 D, ancestry context, IOP 22–25 mmHg interpreted with CCT, borderline CDR/asymmetry and prolonged ocular/systemic steroids. 22
The original quick-review A/B labels are retained as export labels, not certified as separate recommendations for each association. The guideline bases intervals on combined risk and age; men do not receive a different interval solely because their average prevalence is higher. Explain a positive screen, confirm or exclude disease, document the next visit and individualise when necessary. 21 22
The inspected 2024 consensus also considers screening from age 30 in the guideline’s darker-skinned population category. Below 40, it gives 5 years with 1 factor,2–3 years with 2 factors and yearly with≥3. These consensus intervals are distinct from follow-up of known glaucoma or diagnosed ocular hypertension. 22
| Clinical situation | Meaning and next step | Source and limit |
|---|---|---|
| Part A: ROP | Screening and treatment are different decisions | S2k024-010 historical 2020;2026 full text pending |
| GA<31+0 weeks | Historical routine screening; uncertain GA: birthweight<1500g | S2k024-0102020; reconcile 2026 |
| Vascular front in zoneI | Historical weekly screening; earlier if progression | S2k024-0102020 |
| ROP with plus | Historical weekly review and urgent treatment assessment | S2k024-0102020; type 1 framework |
| ZoneI with plus | Treatment-requiring framework irrespective of stage | ETROP/type 1; current local plan |
| ZoneI stage 3 without plus | Treatment-requiring framework | ETROP/type 1 |
| ZoneII stage 3+ | Original early treatment from 1 clock hour; do not wait for threshold; type 1 also includes 2+ | Historical guideline and ETROP distinct |
| A-ROP, historical AP-ROP | Urgent specialist treatment, sometimes within 24 hours | ICROP3 classification; urgency individual |
| After anti-VEGF | Continue specialist reviews beyond due date as needed; delayed reactivation | Therapy-specific follow-up, not untreated stopping rule |
| Part B: Adult open-angle risk | Negative screen after excluding glaucoma | S2e045-0152024; consensus intervals |
| Age 40–59, no additional factor | Every 5 years | S2e045-015 recommendation 4-11, LoE3 |
| Age≥60, no additional factor | Every 2–3 years | S2e045-015 recommendation 4-11, LoE3 |
| Age 40–59 with 1 factor | Every 2–3 years | S2e045-015 recommendation 4-12, LoE3 |
| Age≥60 with 1 factor | Every 1 year | S2e045-015 recommendation 4-12, LoE3 |
| Age≥40 with≥2 factors | Every 1 year | S2e045-015 recommendation 4-12, LoE3 |
| Age 50, myopia magnitude≥4D | 1 additional factor: every 2–3 years after excluding disease | S2e045-015 consensus example |
| Age 45, first-degree family history and CDR asymmetry≥0.2 | 2 additional factors: every 1 year after excluding disease | S2e045-015 consensus example |
| PEX or applanation IOP>25mmHg | At least yearly screening; known OHT needs individual management | S2e045-015 recommendation 4-14, LoE3 |
What are the main learning points?
Keep ROP eligibility, treatment indication and post-treatment follow-up separate. In adult glaucoma screening, confirm suspicious findings and distinguish strong recommendations from the lower evidence supporting interval choices.
When is assessment urgent?
Rapidly progressive ROP needs urgent specialist assessment; do not miss a scheduled neonatal examination. Sudden visual loss, severe pain or new field loss in an adult needs prompt assessment.
References and access status
- 1DOG/AWMF024-010 screening, July 2026 listing
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Current edition located through the official DOG listing; complete clinical text inaccessible. No agreement of the historical schedule with 2026 is claimed.
- 2German S2k ROP screening 2020, GNPI-hosted PDF
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual PDF downloaded; printedpp 1–17 clinical text/glossary and selected tables/references read. Historical guideline; figures/methods not all inspected. Original expired AWMF link retained in the source inventory.
- 3RCPCH UK screening summary, revised October 2024
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual recommendation summary printedpp 3–8 read; full guideline methods/appendices and later service pages unread. UK-specific, not a substitute for current German guidance.
- 4ICROP3, 2021; PMID 34247850
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract and selected downloaded preproof text pp 2–5/Table 1 read; actual printedp 3/Figure 1 visually inspected. Remaining figures/supplements/main text not completely read. Expert classification consensus.
- 5ETROP early treatment, 2003; PMID 14662586
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read. Main report, paired-eye analysis details, protocol and supplements unread; nine-month grating acuity is not long-term ordinary acuity.
- 6BEAT-ROP, 2011; PMID 21323540
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read. Full report/protocol/safety data unread. Recurrence by zone and eye/infant denominators must remain distinct.
- 7RAINBOW, 2019; PMID 31522845
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read. Primary superiority test not met; full methods, protocol, outcome adjudication and supplements unread. Novartis sponsorship.
- 8FIREFLEYE, 2022; PMID 35881122
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read.118 randomised/113 treated; non-inferiority not met. Main report/SAP/protocol and full safety data unread.
- 9NeOProM oxygen-target IPD meta-analysis, 2018; PMID 29872859
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read; full IPD methods, individual trial reports and supplements unread. Competing mortality, different endpoint denominators and multiple secondary endpoints matter.
- 10IGF-1/IGFBP-3 phase 2 randomised trial; PMID 30471715
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read; full report/protocol unread. Primary ROP outcome negative for the tested regimen; exposure attainment and secondary outcomes limit inference.
- 11German S1 ROP therapy 2025, v1.2; corrected 12 January 2026
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual indexed title/TOC and selected clinical text printedpp 5–18 plus selected refs read. Direct local download was HTML denial, not PDF; figures/COI/methods not completely inspected. A suspected dilution inconsistency is documented in the evidence ledger; no recipe adopted.
- 12EMA Lucentis and product-specific EU ROP information
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Selected official Lucentis overview text read. Selected current English EMA Eylea ROP label access carried from parent 017 source work, not a new full 019 label pass. Complete current German product information/device instructions remain pending; see evidence ledger for Eylea source.
- 13BDNF genetic association, 2014; PMID 25118269
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Selected indexed primary abstract/discussion excerpts only. Complete report, confounding/multiplicity and functional replication appraisal pending; not a validated screening test.
- 14FZD4/BDNF association, 2018; PMID 29465286
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read;97 neonates, FZD4 association and larger-study confirmation requested. Full report unread; does not validate every BDNF claim.
- 15Neurotrophin polymorphism cohort, 2025; PMID 39940677
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read;396 preterms, exploratory NGF/TH/BDNF associations. Full report/adjustment/multiplicity unread; confidence intervals for quoted abstract ORs absent there.
- 16RAINBOW five-year extension, 2024; PMID 38638400
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read; full tables/protocol unread. Extension selection, attrition and differing vision tests limit inference. The abstract OR direction for high myopia needs full-table clarification; raw counts are retained instead.
- 17EMA Eylea follow-up assessment report
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Located and selected indexed follow-up commitment text only; no complete five-year primary report or full regulator assessment appraisal claimed.
- 18Historical CRYO-ROP source attribution in German 2020 guideline
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual guideline p 5 and refs 9/10 identify 5½year 1996 and 10 year 2001 reports. Zone-specific primary tables/denominators unread. Developmental reference 28 identifies Hughes 2000, also not fully read; retain the 13 vs 16 week discrepancy.
- 19Original adult RD prophylaxis reference — not a ROP guideline
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Original reference retained for source reconciliation, not used to establish ROP treatment. The separate unlinked original item S1.pdf remains unidentified; no title or source access is invented.
- 20Immutable original export; own complete ROP export; same clinical lecture as 019 after excluding two nonclinical notices
Historical 226-retinopathy-prematurity appraisal reused; not new full-source access. Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 21Immutable original export; S2e risk and early-detection lecture; examiner role unverified
Historical 225-open-angle-risk-screening appraisal reused; not new full-source access. Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 22DOG/BVA S2e 045-015, 3 March 2024
Historical 225-open-angle-risk-screening appraisal reused; not new full-source access. Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Selected extracted original PDF text read 15 November 2026: scope p1, incidence table p8, selected PEX/prevalence p13–14, steroids and disc findings p16–18, recommendations and intervals p19–27. Not the complete 34-page report or all cited studies; source table layout needs image confirmation.
- 23OHTS 2002; PMID 12049574
Historical 225-open-angle-risk-screening appraisal reused; not new full-source access. Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Historical full-text appraisal from review 005 on 2–6 October 2026 and Issue 161 notes reused; not newly read. Open treatment and masked endpoint assessment distinguished.
- 24Brandt et al. CCT-adjusted IOP and OHTS prediction. 2012; PMID 21705084
Historical 225-open-angle-risk-screening appraisal reused; not new full-source access. Historical 161-glaucoma-risk-screening appraisal reused; not new full-source access. Historical review 005 full-text appraisal reused, with complete-case and delayed-CCT limits. Risk-model discrimination is not measurement accuracy; no new full-text claim.
- 25Immutable original export; WBO risk/screening export; examiner identity not verified
Historical 225-open-angle-risk-screening appraisal reused; not new full-source access. Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 26Immutable original export; combined ROP and adult open-angle risk export; own S2k and S2e attributions require version-specific reading
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
Original lecture link
For patients
Premature infants need scheduled retinal checks even without visible symptoms. Adults can also have optic-nerve damage before noticing it; an abnormal screening result first requires confirmation.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Rapidly progressive ROP needs urgent specialist assessment; do not miss a scheduled neonatal examination. Sudden visual loss, severe pain or new field loss in an adult needs prompt assessment.
Rapidly progressive ROP needs urgent specialist assessment; do not miss a scheduled neonatal examination. Sudden visual loss, severe pain or new field loss in an adult needs prompt assessment.